Add Depakote to Burgeoning List of Illegally Marketed Drugs

by Anthony Chicotel, CANHR Staff Attorney

In what has become a disturbingly recurrent pattern, Abbott Labs has agreed to pay $1.6 billion settlement to the federal government and several states for illegally marketing a psychotropic drug as a treatment for dementia (among other things). Abbott’s anti-seizure drug Depakote has no FDA approval as a treatment for dementia nor is there any evidence that it is safe or effective for dementia. In fact, the one clinical trial that Abbott attempted had to stop due to “increased incidence of adverse events.” Nevertheless, Abbott “trained its sales force to promote Depakote to . . . nursing homes,” targeting dementia patients.

As part of the settlement, Abbott pled guilty to misdemeanor misbranding, although it does not appear that any of its executives are going to jail. About $59 million of the settlement is going to California.

While the settlement was widely reported, not many stories mention why Depakote was so eagerly welcomed by nursing home doctors and staff: it comes in a “sprinkle” form that is easy to place surreptitiously in a resident’s food.

The day the settlement was announced, Abbott’s stock price rose ten cents to close at $62.51 per share.


About achicotel

Anthony Chicotel is a staff attorney for CANHR. His areas of expertise include the rights of long-term care residents, nursing home litigation, health care decision-making, and conservatorships.
Print this page.

Responses to CANHR blog postings do not reflect the opinions of CANHR or its staff members.

Leave a Reply